Extracellular vesicles in atherothrombosis: From biomarkers and precision medicine to therapeutic targets

Immunol Rev. 2022 Nov;312(1):6-19. doi: 10.1111/imr.13127. Epub 2022 Aug 22.

Abstract

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of global mortality. Extracellular vesicles (EVs) are small phospholipid vesicles that convey molecular bioactive cargoes and play essential roles in intercellular communication and, hence, a multifaceted role in health and disease. The present review offers a glimpse into the current state and up-to-date concepts on EV field. It also covers their association with several cardiovascular risk factors and ischemic conditions, being subclinical atherosclerosis of utmost relevance for prevention. Interestingly, we show that EVs hold promise as prognostic and diagnostic as well as predictive markers of ASCVD in the precision medicine era. We then report on the role of EVs in atherothrombosis, disentangling the mechanisms involved in the initiation, progression, and complication of atherosclerosis and showing their direct effect in the context of arterial thrombosis. Finally, their potential use for therapeutic intervention is highlighted.

Keywords: atherosclerosis; extracellular vesicles; inflammation; ischemic disease; microvesicles; thrombosis.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Atherosclerosis* / diagnosis
  • Atherosclerosis* / therapy
  • Biomarkers
  • Extracellular Vesicles*
  • Humans
  • Phospholipids
  • Precision Medicine

Substances

  • Biomarkers
  • Phospholipids